Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)
Clinical trial NCT07241403 · COMPLETED
Trial details
- NCT number
- NCT07241403
- Sponsor
- Second Affiliated Hospital of Nanchang University
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2018-01-01
- Primary completion
- 2024-12-30
- Enrollment
- 698
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.